---

Historical Fundamental Stock Analysis of Hospira, Inc. (HSP)

Hospira, Inc. (former NYSE ticker: HSP) was a major global specialty pharmaceutical and medication delivery company that was a standalone entity from 2004 (when it was spun off from Abbott Laboratories) until its acquisition by Pfizer in 2015.

Historical Fundamental Stock Analysis of Hospira, Inc. (HSP)

The fundamental value proposition of Hospira was centered on its leadership in two high-growth, high-barrier-to-entry segments of the healthcare market: Specialty Injectable Pharmaceuticals (SIP) and Biosimilars.

I. Business Model and Core Segments (Pre-Acquisition)

Hospira's business was strategically positioned to capture revenue in hospital-based care settings globally, with a significant concentration in the Americas.

1. Specialty Injectable Pharmaceuticals (SIP)

This was Hospira's largest revenue segment. It focused on generic sterile injectables, including products for acute care, pain management, and oncology. This business was attractive because:

• High Barrier to Entry: Manufacturing sterile injectable drugs is complex, requiring high-quality standards and specialized facilities that are difficult and expensive for competitors to build and maintain. Hospira was a recognized leader in this field, giving it a degree of pricing power unusual for a generics company.

• Growing Market: The global market for generic sterile injectables was projected to grow significantly due to an aging population and the expiration of patents for many branded injectable drugs.

2. Biosimilars

Hospira was an early and global leader in the emerging biosimilars market, which was a key driver of the high acquisition price. Biosimilars are highly similar versions of already approved biological medicines (like insulin or monoclonal antibodies).

• Strategic Pipeline: Hospira had a robust biosimilars pipeline and existing commercial experience in Europe (where the market developed faster than in the U.S.) through its partnership with Celltrion.

• Massive Opportunity: Analysts projected the global market for biosimilars to reach significant valuations, as major biologic patents were set to expire, creating a massive opportunity for the first companies to market with approved copies.

3. Medication Management Systems (MMS)

This segment included infusion technologies, such as IV pumps, solutions, and devices. This business provided a complementary revenue stream and strengthened Hospira's presence within hospitals, often integrating its generic injectable drug products with its proprietary infusion devices. (Note: Pfizer later sold this specific business unit to ICU Medical in 2017).

---

II. Financial and Valuation Analysis Factors

Hospira's fundamental valuation was driven by its market leadership and growth potential, despite manufacturing and regulatory challenges it faced in the years leading up to the acquisition.

1. Revenue and Growth Metrics

In the Last Twelve Months (LTM) leading up to the acquisition announcement, Hospira's revenue was approximately $4.4 billion.

• Growth Trajectory: The SIP and Biosimilars segments offered a more sustainable, mid-to-high single-digit revenue growth trajectory compared to the general pharmaceutical industry, making it highly attractive to a large company like Pfizer looking to boost its Global Established Pharmaceutical (GEP) division.

• Market Position: Hospira’s near-term growth was primarily expected to be driven by its generic sterile injectables business, which was poised to capture market share from competitors struggling with quality issues.

2. Profitability and Operating Efficiency

While generally profitable, Hospira had encountered manufacturing compliance issues with the FDA, which resulted in remediation costs and occasional product supply disruptions.

• Quality Challenges: Analysts often applied a discount to Hospira's valuation due to these regulatory risks. The acquisition by Pfizer, with its global scale and world-class manufacturing expertise, was expected to resolve these issues and improve long-term profitability and operating efficiency, which later translated into Pfizer's anticipated $800 million in annual cost synergies from the merger.

• EBITDA Multiple: Given the cash acquisition price of $17 billion, the valuation multiple paid by Pfizer reflected not just the current financials, but a significant premium for the future growth prospects of the biosimilars pipeline and the projected cost synergies.

3. Balance Sheet Health

As an independent company, Hospira managed a typical pharmaceutical balance sheet. While debt was a factor, the stable, high-margin nature of its core business provided reliable cash flow to service its obligations, making it a viable acquisition target for an all-cash purchase.

---

III. Strategic Rationale for the Acquisition (The Final Analysis)

The ultimate fundamental analysis for Hospira's shareholders was the acquisition by Pfizer. The $90 per share cash price represented a substantial 39% premium over Hospira's stock closing price just before the announcement.

From the acquirer's (Pfizer's) perspective, the fundamental value of Hospira was:

Key Fundamental Asset	Acquirer's Value Proposition
SIP & Injectable Portfolio	Market Leadership & Scale. It immediately vaulted Pfizer into a leading global position in the high-growth, $70 billion generic sterile injectables market.
Biosimilars Business	Future Growth Engine. It significantly enhanced Pfizer's presence in biosimilars, which was viewed as the next wave of generic drug revenue.
Manufacturing Footprint	Asset Consolidation. Pfizer gained two of the largest sterile injectable manufacturing facilities in the world, which, when integrated with its quality systems, would solidify the combined company's supply chain.

In summary, a historical fundamental analysis of Hospira showed a company with strong product franchises in highly attractive, growing markets, counterbalanced by operational and manufacturing risks. The $90 per share acquisition price validated the belief that the underlying value and growth potential of its biosimilars pipeline and market-leading sterile injectables business were substantial, especially when combined with a global pharmaceutical giant capable of correcting its operational inefficiencies.